Eledon Pharmaceuticals, Inc. (ELDN) Financial Analysis & Valuation | Quarter Chart
Eledon Pharmaceuticals, Inc. (ELDN)
ELDNPrice: $2.92
Fair Value: 🔒
🔒score
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized m... more
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medici... more
Description
Shares
| Market Cap | $175.05M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David-Alexandre C. Gros |
| IPO Date | 2014-09-17 | CAGR | — |
| Employees | 31 | Website | eledon.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ELDN chart loading...
Fundamentals
Technicals
| Enterprise Value | $266.35M | P/E Ratio | -5.62 |
| Forward P/E | -3.86 | PEG Ratio | — |
| P/S Ratio | 25232306.9 | P/B Ratio | 363726.03 |
| P/CF Ratio | -175009.64 | P/FCF Ratio | -147209.29 |
| EPS | $-0.52 | EPS Growth 1Y | 120.1% |
| EPS Growth 3Y | 373.31% | EPS Growth 5Y | -44.09% |
| Revenue Growth 1Y | -31.43% | Gross Margin | 0.5% |
| Operating Margin | -225.16% | Profit Margin | -207.78% |
| ROE | -0.85% | ROA | -0.61% |
| ROCE | -0.75% | Current Ratio | 6.74 |
| Quick Ratio | 6.74 | Cash Ratio | 0.26 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | -3.11 | Piotroski Score | 2 |